Bioinformatic analysis suggests that UGT2B15 activates the Hippo‑YAP signaling pathway leading to the pathogenesis of gastric cancer

Chen,Xuanmin; Li,Defeng; Wang,Nannan; Yang,Meifeng; Liao,Aijun; Wang,Shuling; Hu,Guangsheng; Zeng,Bing; Yao,Yuhong; Liu,Diqun; Liu,Han; Zhou,Weiwei; Xiao,Weisheng; Li,Peiyuan; Ming,Chen; Ping,Song; Chen,Pingfang; Jing,Li; Bai,Yu; Yao,Jun

doi:10.3892/or.2018.6604

Bioinformatic analysis suggests that UGT2B15 activates the Hippo‑YAP signaling pathway leading to the pathogenesis of gastric cancer

Authors:
- Xuanmin Chen
- Defeng Li
- Nannan Wang
- Meifeng Yang
- Aijun Liao
- Shuling Wang
- Guangsheng Hu
- Bing Zeng
- Yuhong Yao
- Diqun Liu
- Han Liu
- Weiwei Zhou
- Weisheng Xiao
- Peiyuan Li
- Chen Ming
- Song Ping
- Pingfang Chen
- Li Jing
- Yu Bai
- Jun Yao
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of University of South China, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Gastroenterology, The 2nd Clinical Μedicine College (Shenzhen People's Hospital) of Jinan University, Shenzhen, Guangdong 518020, P.R. China, Department of Hematology, The First Affiliated Hospital of University of South China, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Gastroenterology, Shanghai Hospital, Second Military Medical University, Shanghai 200433
Published online on: July 26, 2018 https://doi.org/10.3892/or.2018.6604
Pages: 1855-1862
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most common malignancies that threatens human health. As the molecular mechanisms unerlying GC are not completely understood, identification of genes related to GC could provide new insights into gene function as well as potential treatment targets. We discovered that UGT2B15 may contribute to the pathogenesis and progression of GC using GEO data and bioinformatic analysis. Using TCGA data, UGT2B15 mRNA was found to be significantly overexpressed in GC tissues; patients with higher UGT2B15 had a poorer prognosis. It was further discovered that UGT2B15 and FOXA1 were both upregulated, and UGT2B15 and Foxa1 were positively correlated in GC. It is known that Foxa1 is a vital threshold to activate the Hippo‑YAP signaling pathway. In addition, we suggest that a potential molecular mechanisms includes UGT2B15 which may upregulate Foxa1, activate the Hippo‑YAP signaling pathway and contribute to the development of GC. Taken together, our findings demonstrate that UGT2B15 may be an oncogene in GC and is a promising therapeutic target for cancer treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Yan C, Zhu M, Huang T, Yu F and Jin G: Genome-wide association studies identified loci contribute to phenotypic variance of gastric cancer. Gut. 2017.
3	Huang LY, Wang X, Cui XF, Li H, Zhao J, Wu CC, Min L, Zhou Z, Wan L, Wang YP, et al: IRTKS is correlated with progression and survival time of patients with gastric cancer. Gut. 2017.
4	Zhang X and Xu W: Neutrophils diminish T-cell immunity to foster gastric cancer progression: The role of GM-CSF/PD-L1/PD-1 signalling pathway. Gut. 66:1878–1880. 2017. View Article : Google Scholar : PubMed/NCBI
5	Gan L, Meng J, Xu M, Liu M, Qi Y, Tan C, Wang Y, Zhang P, Weng W, Sheng W, et al: Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin beta4/FAK/SOX2/HIF-1alpha signaling pathway in gastric cancer. Oncogene. 37:744–755. 2017. View Article : Google Scholar : PubMed/NCBI
6	Brower V: Apatinib in treatment of refractory gastric cancer. Lancet Oncol. 17:e1372016. View Article : Google Scholar : PubMed/NCBI
7	Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, et al: Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol. 33:3858–3865. 2015. View Article : Google Scholar : PubMed/NCBI
8	Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, et al: Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia. Cancer Cell. 32:490–505. 2017. View Article : Google Scholar : PubMed/NCBI
9	Buttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, Lopez-Rios F, Penault-Llorca F, et al: Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 35:3867–3876. 2017. View Article : Google Scholar : PubMed/NCBI
10	Ge W, Zhao K, Wang X, Li H, Yu M, He M, Xue X, Zhu Y, Zhang C, Cheng Y, et al: iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for keap1 binding. Cancer Cell. 32:561–573. 2017. View Article : Google Scholar : PubMed/NCBI
11	Sidaway P: Breast cancer: LAG3 expression indicates favourable outcomes. Nat Rev Clin Oncol. 14:7122017. View Article : Google Scholar
12	Shou Z, Jin X, He X, Zhao Z, Chen Y, Ye M and Yao J: Overexpression of Musashi-1 protein is associated with progression and poor prognosis of gastric cancer. Oncol Lett. 13:3556–3566. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shimada Y, Okumura T, Sekine S, Moriyama M, Sawada S, Matsui K, Yoshioka I, Hojo S, Yoshida T, Nagata T, et al: Expression analysis of iPS cell-inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res. 32:5507–5514. 2012.PubMed/NCBI
14	Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T and Aburatani H: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 62:233–240. 2002.PubMed/NCBI
15	Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bieche I, Grisard E, Josserand V, Coll JL, Roux P, et al: ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res. 72:3593–3606. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sun Y, Zheng S, Torossian A, Speirs CK, Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys. 82:e563–572. 2012. View Article : Google Scholar : PubMed/NCBI
17	Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 10:99–111. 2006. View Article : Google Scholar : PubMed/NCBI
18	Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, et al: Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Res. 76:5881–5893. 2016. View Article : Google Scholar : PubMed/NCBI
19	Grosse L, Paquet S, Caron P, Fazli L, Rennie PS, Belanger A and Barbier O: Androgen glucuronidation: An unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Res. 73:6963–6971. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hwang MS, Lee SJ, Kim WY, Jeong HE and Shin JG: Genetic variations in UDP-glucuronosyltransferase 2B15 in a Korean population. Drug Metab Pharmacokinet. 29:105–109. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pfeiffer MJ, Smit FP, Sedelaar JP and Schalken JA: Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med. 17:657–664. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sutiman N, Lim JS, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Ang PC, Dent R, et al: Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on Tamoxifen disposition in Asian breast cancer patients. Clin Pharmacokinet. 55:1239–1250. 2016. View Article : Google Scholar : PubMed/NCBI
23	Wang LL, Xiu YL, Chen X, Sun KX, Chen S, Wu DD, Liu BL and Zhao Y: The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression. Tumour Biol. 39:10104283177062102017.PubMed/NCBI
24	Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C and Li XB: GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Hum Pathol. 47:26–31. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ren H, Zhang P, Tang Y, Wu M and Zhang W: Forkhead box protein A1 is a prognostic predictor and promotes tumor growth of gastric cancer. Onco Targets Ther. 8:3029–3039. 2015.PubMed/NCBI